机译:miR-449a和miR-449b是E2F1的直接转录靶标,并通过靶向CDK6和CDC25A的反馈环负调控pRb-E2F1的活性
Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;
Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;
Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;
Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;
Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;
Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672;
Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Singapore 138672|Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597;
CDC25A; CDK6; DZNep; E2F1; miR-449;
机译:miR-449a和miR-449b是E2F1的直接转录靶标,并通过靶向CDK6和CDC25A通过反馈环负调控pRb-E2F1活性。
机译:E2f1,E2f2和E2f3通过依赖于p53的负反馈环控制E2F目标表达和细胞增殖
机译:RBM38是E2F1的直接转录靶标,可限制E2F1诱导的增殖
机译:基于脑电图的镜像视觉目标定向运动过程中皮层活动的分析
机译:靶向AR3和E2F1之间的串扰作为耐药前列腺癌的前瞻性疗法
机译:miR-449a和miR-449b是E2F1的直接转录靶标并通过靶向CDK6和CDC25A的反馈环负调控pRb-E2F1的活性
机译:miR-449a和miR-449b是E2F1的直接转录靶标,并通过靶向CDK6和CDC25A的反馈环负调控pRb-E2F1的活性